Disease
4 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
SEP 7, 2026 · REVIEW
Frontiers in Medicine
A narrative review synthesizing adverse event profiles across 14 NCCN-recommended systemic therapies for cutaneous T-cell lymphoma, designed to inform clinical treatment selection and monitoring rather than report new efficacy data.
SEP 1, 2026 · JOURNAL ARTICLE
Materials Today Bio
Early-stage preclinical work demonstrating proof-of-concept in cell and animal models; no human data, surrogate endpoints only, and no direct clinical comparator.
AUG 14, 2026 · JOURNAL ARTICLE
Blood Cancer Discovery
A sound preclinical study demonstrating in vitro and in vivo proof-of-concept for a novel CAR T approach targeting an intracellular antigen across diverse HLA alleles, but without clinical efficacy data or human trial results.
This is an editorial commentary describing a resource paper, not a primary research study reporting empirical findings, effect sizes, or clinical outcomes to evaluate.